New Zealand

New Zealand does not offer general legal clinical access to classical psychedelics. Psilocybin, LSD, mescaline and related compounds remain Class A controlled drugs, MDMA is Class B1, and ketamine is Class C.

Ask Blossom about this country

Key Insights

A concise read of the policy, research, and stakeholder signals shaping psychedelic medicine in New Zealand.

1
New Zealand is not an Australia-style psilocybin or MDMA access jurisdiction. Classical psychedelics remain controlled and visible use is research-led.
2
Esketamine is approved but not routinely publicly funded; approval and reimbursement are separate gates.
3
Ketamine for depression is off-label, with funded public schedule entries tied to emergency or palliative pain uses rather than depression.
4
The strongest academic signals are LSD microdosing, oral ketamine models, MDMA-assisted therapy in advanced cancer and a marae-setting psilocybin pilot.
5
Auckland is the clearest single hub for LSD psychopharmacology, while Christchurch and Dunedin are central for ketamine and MDMA clinical work.
6
New Zealand's distinctive contribution is culturally grounded protocol design, especially the Matai marae-setting psilocybin pilot.

Research Snapshot

Blossom currently tracks 24 psychedelic clinical trials connected to New Zealand, including 5 active studies.

Active trials: 5
Total trials: 24
Stakeholders: 4
Events: 0

Top Compounds

Ketamine(13)
MDMA(3)
Psilocybin(3)
LSD(2)
Ibogaine(1)

Active Trial Preview

View all trials →

Medical Access Snapshot

New Zealand keeps classical psychedelics tightly controlled. Esketamine is approved but not routinely publicly funded, ketamine depression care is off-label, and psilocybin, MDMA and LSD access is limited to regulated research or narrow exception routes.

View trials→View stakeholders→Open access guide→

Regulatory Status

New Zealand remains restrictive for classical psychedelics. The Misuse of Drugs Act places psilocybin, LSD, mescaline and related compounds in Class A, MDMA in Class B1, and ketamine in Class C. Clinical trials require Medsafe and ethics approvals, and unapproved-medicines rules can support named-patient access in limited circumstances, but those provisions do not create market authorisation or a routine psilocybin or MDMA psychiatry pathway. The only clearly approved psychedelic-adjacent psychiatric medicine identified in this review is Spravato/esketamine, which remains supervised and not routinely funded through the public schedule.

History of Research in New Zealand

The documentary history begins with control rather than clinical adoption. The Misuse of Drugs Act 1975 created the class-based regime still used today, with later changes placing MDMA in Class B1 and ketamine in Class C. Those schedules shape research permissions, import, storage, prescribing and criminal exposure. #

Medsafe approval of Spravato in December 2019 created an approved-medicine route for esketamine in treatment-resistant depression and acute depressive crises. That approval did not create routine national reimbursement, and current schedule checks still support an approved-but-unfunded reading. # #

The modern research restart is visible from 2023 onward. Auckland researchers completed LSDDEP1 and published peer-reviewed results, while the LSDDEP2 protocol moved the programme into a controlled Phase II design. At the same time, Otago-linked teams advanced oral ketamine and MDMA-oncology work. # # # #

A second strand is cultural adaptation. The completed Matai pilot of psilocybin administration in healthy volunteers within a marae setting is important because it treats setting, tikanga and Maori health concepts as part of study design. It is a research signal, not a patient-access pathway. #

Auckland, Otago and Matai

Auckland has the strongest single-hub claim because the University of Auckland sponsors the LSDDEP1 and LSDDEP2 depression programme and has visible psychopharmacology expertise. It is the main national node for LSD microdosing research and related methodology. # #

Christchurch and Dunedin form the country's most important translational axis for ketamine and MDMA-related psychiatry. University of Otago-linked work includes oral ketamine plus behavioural activation and the EMMAC advanced-cancer study. # #

Gisborne is smaller but strategically important because of Matai Medical Research Institute's marae-setting psilocybin pilot. Its importance is not volume; it is the explicit attempt to build culturally grounded protocol design into psychedelic research. #

Research Focus

The most visible classical-psychedelic programme is the Auckland LSD work. LSDDEP1 tested low-dose LSD in major depressive disorder in a small open-label design and later reported peer-reviewed mood and pharmacokinetic outcomes. LSDDEP2, described in a published protocol, moved to a triple-blind, active-placebo-controlled Phase II design. # #

Ketamine is the deepest local clinical lane. The University of Otago-linked behavioural-activation trial is testing oral ketamine models in treatment-resistant depression, while New Zealand clinicians and authors have described psychiatric ketamine use as off-label and governance-sensitive. Professional guidance now frames ketamine as a specialist intervention requiring careful service design. # # #

MDMA and psilocybin are narrower but strategically useful. EMMAC is testing MDMA-assisted therapy for mood and anxiety symptoms in advanced-stage cancer, while the Matai psilocybin pilot is most valuable as a culturally specific feasibility and setting study rather than evidence of treatment availability. # #

Key Milestones

1975

The Misuse of Drugs Act creates New Zealand's modern class-based controlled-drug regime.

2005

MDMA is moved into Class B1 controls.

2010

Ketamine is classified as a Class C controlled drug.

2019

Medsafe first approves Spravato in New Zealand.

2023

EMMAC begins as a New Zealand MDMA-assisted therapy study for advanced-stage cancer distress.

2023

LSDDEP1 begins enrolment for low-dose LSD in major depressive disorder.

2024

The LSDDEP2 controlled Phase II protocol is published.

2024

A marae-setting psilocybin pilot receives ethics approval and later completes with 12 healthy volunteers.

2026

LSDDEP1 peer-reviewed results appear, adding a local open-label evidence signal while leaving controlled efficacy unresolved.

Future Outlook

In the next 12-24 months, change is more likely to come from study outputs than from broad legal reform. The local watchlist is LSDDEP2 results, reporting from the Matai psilocybin pilot, further recruitment and results from Otago ketamine work, and any clearer operational update from EMMAC. # # # #

The reimbursement base case remains cautious. Esketamine is approved, but current public funding checks do not show routine public schedule access. The 2025 unapproved-medicines guidance may broaden some prescriber handling, but it does not override controlled-drug law or create a normal psilocybin or MDMA access route. # # #

Professional capacity may improve faster than patient access. New Zealand now has enough investigators, trial therapists and ketamine-service experience for governance and training standards to mature, but practical access will still depend on funding, controlled-drug compliance and service capacity. # #